Construct: ORF ccsbBroadEn_10962

Construct Description:

Construct Type:
ORF
Other Identifiers:
ORF004378.1_s300c1, BRDN0000389973
DNA Barcode:
None
Epitope Tag:
None
Notes:
No stop codon in insert

Originally Annotated References:

Gene:
MEF2A (4205)

Vector Information:

Vector Backbone:
pDONR223
Pol II Cassette 1:
n/a
Pol II Cassette 2:
n/a
Selection Marker:
n/a
Visible Reporter:
n/a
Epitope Tag:
n/a

Current transcripts matched by this ORF:

Taxon Gene Symbol Description Transcript Nuc. Match %[?] Prot. Match %[?] Match Diffs[?]
1 human 4205 MEF2A myocyte enhancer factor 2A NM_001130928.2 97.2% 97.4% 1_33del;657T>C;663G>A
2 human 4205 MEF2A myocyte enhancer factor 2A XM_011521587.2 97.2% 97.4% 1_33del;657T>C;663G>A
3 human 4205 MEF2A myocyte enhancer factor 2A NM_001130927.3 95.4% 95.6% (many diffs)
4 human 4205 MEF2A myocyte enhancer factor 2A NM_001365209.1 95.4% 95.6% (many diffs)
5 human 4205 MEF2A myocyte enhancer factor 2A XM_017022195.1 91.5% 90.2% (many diffs)
6 human 4205 MEF2A myocyte enhancer factor 2A XM_011521585.2 89.9% 87.8% (many diffs)
7 human 4205 MEF2A myocyte enhancer factor 2A XM_017022199.1 89.3% 86.5% (many diffs)
8 human 4205 MEF2A myocyte enhancer factor 2A XM_017022200.1 88.1% 87.4% (many diffs)
9 human 4205 MEF2A myocyte enhancer factor 2A XM_017022201.1 88.1% 87.4% (many diffs)
10 human 4205 MEF2A myocyte enhancer factor 2A XM_017022196.1 87.6% 84.9% (many diffs)
11 human 4205 MEF2A myocyte enhancer factor 2A XM_017022197.2 86.5% 85.7% (many diffs)
12 human 4205 MEF2A myocyte enhancer factor 2A XM_017022198.2 86.5% 85.7% (many diffs)
13 human 4205 MEF2A myocyte enhancer factor 2A XM_017022202.1 83.8% 84% (many diffs)
14 human 4205 MEF2A myocyte enhancer factor 2A NM_001130926.2 83.8% 82.8% (many diffs)
15 human 4205 MEF2A myocyte enhancer factor 2A NM_001171894.3 83.8% 82.8% (many diffs)
16 human 4205 MEF2A myocyte enhancer factor 2A NM_001352614.2 83.8% 82.8% (many diffs)
17 human 4205 MEF2A myocyte enhancer factor 2A NM_001352615.2 83.8% 82.8% (many diffs)
18 human 4205 MEF2A myocyte enhancer factor 2A NM_001365208.1 83.8% 82.8% (many diffs)
19 human 4205 MEF2A myocyte enhancer factor 2A NM_001319206.2 82.5% 81.5% (many diffs)
20 human 4205 MEF2A myocyte enhancer factor 2A NM_001352616.2 82.5% 81.5% (many diffs)
21 human 4205 MEF2A myocyte enhancer factor 2A NM_001365205.1 82.5% 81.5% (many diffs)
22 human 4205 MEF2A myocyte enhancer factor 2A NM_001352617.2 81.5% 76.7% (many diffs)
23 human 4205 MEF2A myocyte enhancer factor 2A NM_001365207.1 81.5% 76.7% (many diffs)
24 human 4205 MEF2A myocyte enhancer factor 2A NM_005587.4 81.5% 76.7% (many diffs)
25 human 4205 MEF2A myocyte enhancer factor 2A NM_001352618.2 80.9% 76.1% (many diffs)
26 human 4205 MEF2A myocyte enhancer factor 2A NM_001365206.1 80.9% 76.1% (many diffs)
27 human 4205 MEF2A myocyte enhancer factor 2A NM_001365203.1 80.2% 75.5% (many diffs)
28 human 4205 MEF2A myocyte enhancer factor 2A NM_001365204.1 80.2% 75.5% (many diffs)
29 human 4205 MEF2A myocyte enhancer factor 2A XM_011521582.2 80.2% 75.5% (many diffs)
30 human 4205 MEF2A myocyte enhancer factor 2A XM_017022191.1 80.2% 75.5% (many diffs)
31 human 4205 MEF2A myocyte enhancer factor 2A NM_001365201.1 79.7% 74.9% (many diffs)
32 human 4205 MEF2A myocyte enhancer factor 2A NM_001365202.1 79.7% 74.9% (many diffs)
33 human 4205 MEF2A myocyte enhancer factor 2A XM_011521572.2 79.7% 74.9% (many diffs)
34 human 4205 MEF2A myocyte enhancer factor 2A XM_011521573.2 79.7% 74.9% (many diffs)
35 human 4205 MEF2A myocyte enhancer factor 2A XM_011521577.2 79.7% 74.9% (many diffs)
36 human 4205 MEF2A myocyte enhancer factor 2A XM_011521578.2 79.7% 74.9% (many diffs)
37 human 4205 MEF2A myocyte enhancer factor 2A XM_011521579.2 79.7% 74.9% (many diffs)
38 human 4205 MEF2A myocyte enhancer factor 2A XM_011521590.2 40.9% 34.7% (many diffs)
39 human 4205 MEF2A myocyte enhancer factor 2A XR_001751289.1 38.8% (many diffs)
40 human 4205 MEF2A myocyte enhancer factor 2A NM_001365211.2 32.9% 29.1% (many diffs)
41 human 4205 MEF2A myocyte enhancer factor 2A NM_001365210.2 31% 23.2% (many diffs)
42 human 4205 MEF2A myocyte enhancer factor 2A XM_005254916.3 30.8% 23% (many diffs)
43 mouse 17258 Mef2a myocyte enhancer factor 2A NM_001291196.1 75.7% 80.3% (many diffs)
44 mouse 17258 Mef2a myocyte enhancer factor 2A NM_001291195.1 75.3% 78.4% (many diffs)
45 mouse 17258 Mef2a myocyte enhancer factor 2A NM_001033713.2 74.1% 77.2% (many diffs)
46 mouse 17258 Mef2a myocyte enhancer factor 2A XM_006540686.3 74.1% 77.2% (many diffs)
47 mouse 17258 Mef2a myocyte enhancer factor 2A XM_017322011.1 74.1% 77.2% (many diffs)
48 mouse 17258 Mef2a myocyte enhancer factor 2A NM_001291191.1 73.2% 72.3% (many diffs)
49 mouse 17258 Mef2a myocyte enhancer factor 2A NM_001291192.1 73.2% 72.3% (many diffs)
50 mouse 17258 Mef2a myocyte enhancer factor 2A XM_011250814.2 73.2% 72.3% (many diffs)
51 mouse 17258 Mef2a myocyte enhancer factor 2A XM_006540684.3 72% 71.2% (many diffs)
52 mouse 17258 Mef2a myocyte enhancer factor 2A XM_006540685.3 72% 71.2% (many diffs)
Download CSV

Sequence Information

Note: uppercase bases indicate empirically verified sequence.

ORF start:
66
ORF end:
1320
ORF length:
1254
Sequence:
1gttcgttgca acaaattgat gagcaatgct tttttataat gccaaCTTTG TACAAAAAAG
61TTGGCATGGA TGAAAGGAAC CGACAGACTT TAAGAAAGAA AGGCCTTAAT GGTTGTGAGA
121GCCCTGATGC TGACGATTAC TTTGAGCACA GTCCACTCTC GGAGGACAGA TTCAGCAAAC
181TAAATGAAGA TAGTGATTTT ATTTTCAAAC GAGGCCCTCC TGGTCTGCCA CCTCAGAACT
241TTTCAATGTC TGTCACAGTT CCAGTGACCA GCCCCAATGC TTTGTCCTAC ACTAACCCAG
301GGAGTTCACT GGTGTCCCCA TCTTTGGCAG CCAGCTCAAC GTTAACAGAT TCAAGCATGC
361TCTCTCCACC TCAAACCACA TTACATAGAA ATGTGTCTCC TGGAGCTCCT CAGAGACCAC
421CAAGTACTGG CAATGCAGGT GGGATGTTGA GCACTACAGA CCTCACAGTG CCAAATGGAG
481CTGGAAGCAG TCCAGTGGGG AATGGATTTG TAAACTCAAG AGCTTCTCCA AATTTGATTG
541GAGCTACTGG TGCAAATAGC TTAGGCAAAG TCATGCCTAC AAAGTCTCCC CCTCCACCAG
601GTGGTGGTAA TCTTGGAATG AACAGTAGGA AACCAGATCT TCGAGTTGTC ATCCCCCCTT
661CAAGCAAGGG CATGATGCCT CCACTAAACA CCCAAAGGAT CAGTAGTTCT CAAGCCACTC
721AACCTCTTGC TACCCCAGTC GTGTCTGTGA CAACCCCAAG CTTGCCTCCG CAAGGACTTG
781TGTACTCAGC AATGCCGACT GCCTACAACA CTGATTATTC ACTGACCAGC GCTGACCTGT
841CAGCCCTTCA AGGCTTCAAC TCGCCAGGAA TGCTGTCGCT GGGACAGGTG TCGGCCTGGC
901AGCAGCACCA CCTAGGACAA GCAGCCCTCA GCTCTCTTGT TGCTGGAGGG CAGTTATCTC
961AGGGTTCCAA TTTATCCATT AATACCAACC AAAACATCAG CATCAAGTCC GAACCGATTT
1021CACCTCCTCG GGATCGTATG ACCCCATCGG GCTTCCAGCA GCAGCAGCAG CAGCAGCAGC
1081AGCAGCAGCC GCCGCCACCA CCGCAGCCCC AGCCACAACC CCCGCAGCCC CAGCCCCGAC
1141AGGAAATGGG GCGCTCCCCT GTGGACAGTC TGAGCAGCTC TAGTAGCTCC TATGATGGCA
1201GTGATCGGGA GGATCCACGG GGCGACTTCC ATTCTCCAAT TGTGCTTGGC CGACCCCCAA
1261ACACTGAGGA CAGAGAAAGC CCTTCTGTAA AGCGAATGAG GATGGACGCG TGGGTGACCT
1321ACCCAACTTT CTTGTACAAA GTtggcatta taagaaagca ttgcttatca atttgttgca
1381acgaac

Download FASTA (ORF) (Full)

GPP Web Portal Terms of Service

Effective Date: December 8, 2025
By using this site, you agree to our terms and conditions below.

Overview of Terms

The data made available on this website were generated for research purposes and are not intended for clinical or commercial uses. Commercial use (or other use for profit-making purposes) of the GPP Web Portal and its tools, is not permitted under these terms and may require a separate license agreement from Broad or its contributors. For more information, please contact partnering@broadinstitute.org.

The original data may be subject to rights claimed by third parties, including but not limited to, patent, copyright, other intellectual property rights, biodiversity-related access and benefit-sharing rights. It is the responsibility of users of Broad Institute services to ensure that their use of the data does not infringe any of the rights of such third parties.

Any questions or comments concerning these Terms of Use can be addressed to: legal@broadinstitute.org.

By accessing and viewing this GPP Web Portal, you agree to the following terms and conditions:

Attribution

You agree to acknowledge the Broad Institute (e.g., in publications, services or products) for any of your use of its online services, databases or software in accordance with good scientific practice. You agree to use the acknowledgment wording provided for the relevant tools as indicated on the FAQ for each tool.

Updating the Terms of Use

We reserve the right to update these Terms of Use at any time. When alterations are inevitable, we will attempt to give reasonable notice of any changes by placing a notice on our website, but you may wish to check each time you use the website. The date of the most recent revision will appear on this, the "GPP Web Portal Terms of Use" page. If you do not agree to these changes, please do not continue to use our online services. We will also make available an archived copy of the previous Terms of Use for comparison.

Indemnification and Disclaimer of Warranties

You are using this GPP Web Portal at your own risk, and you hereby agree to hold Broad and its contributors and their trustees, directors, officers, employees, and affiliated investigators harmless for any third party claims which may arise from your use of the GPP Web Portal, the tools available therein, or any portion thereof. Further, you agree to indemnify Broad, its contributors, and its and their trustees, directors, officers, employees, affiliated investigators, students, and affiliates for any loss, costs, claims, damages, or other liabilities arising from any unpermitted commercial or profit-making use you make of the GPP Web Portal. The GPP Web Portal is a research tool and is provided "as is". Broad does not represent that the GPP Web Portal is free of errors or bugs or suitable for any particular tasks.

ANY EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NONINFRINGEMENT, OR THE ABSENCE OF LATENT OR OTHER DEFECTS ARE DISCLAIMED. IN NO EVENT SHALL BROAD OR ITS CONTRIBUTORS BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) ARISING IN ANY WAY OUT OF THE USE OF THE GPP WEB PORTAL, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.

Governing Law

The terms and conditions herein shall be construed, governed, interpreted, and applied in accordance with the internal laws of the Commonwealth of Massachusetts, U.S.A. Furthermore, by accessing, downloading, or using the Database, You consent to the personal jurisdiction of, and venue in, the state and federal courts within Massachusetts with respect to Your download or use of the Database.